OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis

T. E. McAlindon, J. B. Driban*, Y. Henrotin, D. J. Hunter, G. L. Jiang, S. T. Skou, S. Wang, T. Schnitzer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

166 Scopus citations

Abstract

The goal of this document is to update the original OARSI recommendations specifically for the design, conduct, and reporting of clinical trials that target symptom or structure modification among individuals with knee osteoarthritis (OA).To develop recommendations for the design, conduct, and reporting of clinical trials for knee OA we initially drafted recommendations through an iterative process. Members of the working group included representatives from industry and academia. After the working group members reviewed a final draft, they scored the appropriateness for recommendations. After the members voted we calculated the median score among the nine members of the working group who completed the score.The document includes 25 recommendations regarding randomization, blocking and stratification, blinding, enhancing accuracy of patient-reported outcomes (PRO), selecting a study population and index knee, describing interventions, patient-reported and physical performance measures, structural outcome measures, biochemical biomarkers, and reporting recommendations.In summary, the working group identified 25 recommendations that represent the current best practices regarding clinical trials that target symptom or structure modification among individuals with knee OA. These updated recommendations incorporate novel technologies (e.g., magnetic resonance imaging (MRI)) and strategies to address the heterogeneity of knee OA.

Original languageEnglish (US)
Pages (from-to)747-760
Number of pages14
JournalOsteoarthritis and Cartilage
Volume23
Issue number5
DOIs
StatePublished - 2015

Funding

Yves Henrotin – YH received honoraria from Artialis, Bioiberica, Danone, Expanscience, Ibsa, Merck, Pierre Fabre, Synolyne Pharma, Tilman. YH is the founder and owner of Artialis SA a biomarker manufacturer and Synolyne Pharma, two spin-off companies of the University of Liège. YH also received unrestricted educational grant from Bioiberica, Expanscience, Royal Canin, Artialis, and Nestle.

Keywords

  • Clinical trial
  • Consensus statement
  • Knee
  • Osteoarthritis

ASJC Scopus subject areas

  • Rheumatology
  • Biomedical Engineering
  • Orthopedics and Sports Medicine

Fingerprint

Dive into the research topics of 'OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis'. Together they form a unique fingerprint.

Cite this